PCORI funds a kind of research that NIH and industry don't do well — comparative effectiveness studies that ask "which of the options currently available actually works better for which patients?" That's a different question from the one clinical trials typically answer. Regulatory trials compare a new drug to placebo; PCORI funds studies that compare two real-world treatment options head-to-head in the patients who actually receive care. The Q2 2026 cycle has updated priority areas and eligibility structure that differ from prior cycles. If you're developing a proposal, understanding those specifics before you write the LOI saves weeks of wasted effort.
This article is for research investigators and institutional administrators seeking PCORI funding. It does not constitute medical advice. All research must follow applicable regulatory requirements including IRB review.
Summary
PCORI — the Patient-Centered Outcomes Research Institute — distributes approximately $500 million annually to fund comparative effectiveness research: studies designed to help patients and clinicians choose between existing options rather than prove new drugs work better than placebo. Unlike NIH, every PCORI grant requires meaningful patient and stakeholder engagement as a structural element of the research design, not an add-on. The Q2 2026 cycle includes Pragmatic Clinical Studies (up to $30M), targeted PCOR Awards ($750K–$5M), Evidence Synthesis awards (up to $1.5M), and Pipeline to Proposal capacity-building grants for new applicants ($50K–$200K).
ClinicalMetric Analysis
- PCORI's active comparator requirement is a scientific commitment — and choosing the comparator is itself a scientific and political decision that proposals often underinvest in. Sponsors who haven't done formal stakeholder engagement to identify which comparators patients and clinicians consider most clinically meaningful are writing proposals that won't score well at review. The comparator represents the real-world clinical decision being modeled, and reviewers assess whether the study addresses an actual practice choice — not just a statistical contrast. The highest-scoring PCS applications document why the specific comparators were selected and who was involved in that decision.
- PCORI's patient engagement requirement is assessed rigorously — reviewers are specifically trained to distinguish structural engagement from performative mentions of advisory boards. Studies that mention patient and stakeholder advisors in passing without documenting specific contributions to outcome selection, endpoint prioritization, or protocol design are regularly scored poorly. The key scoring distinction is whether engagement occurred at the hypothesis-generation stage (fundable) or at the dissemination stage (not what PCORI is funding for). New applicants should budget for 6–12 months of patient engagement documentation work before submitting a full application.
- The Pipeline to Proposal mechanism is the entry point most misused by new applicants — it's a relationship-building grant, not a data collection grant. PCORI funds P2P explicitly to help new applicants build the stakeholder engagement infrastructure, community partnerships, and co-design processes that make a subsequent full Pragmatic Clinical Study application competitive. Applicants who use P2P to generate preliminary efficacy data are not only misaligning with the mechanism's intent — they're unlikely to score well on the engagement criteria that PCORI's full application reviewers assess most heavily. The P2P grant that produces an organized stakeholder advisory group and a co-designed research question is the fundable full application in two years.
What PCORI Funds — and What It Doesn't
The most important thing to understand before writing a PCORI proposal is what the agency will not fund. PCORI does not fund basic science, animal studies, or efficacy trials comparing a treatment to placebo. It funds comparative effectiveness research — studies with at least two active treatment comparators, conducted in real-world patient populations, generating evidence about which option works better for which patients under what circumstances.
The word "patient-centered" in PCORI's name has a specific operational meaning. Outcomes must matter to patients, not just to clinicians or payers. A study comparing biomarker response rates without measuring patient-reported quality of life is unlikely to score well. Reviewers assess whether the study addresses questions that patients themselves have identified as important — ideally documented through formal stakeholder engagement during proposal development. The agencies that do this well treat patient engagement as a scientific methodology, not a public relations requirement.
Q2 2026 Funding Opportunity Breakdown
- Pragmatic Clinical Studies (PCS): PCORI's flagship funding mechanism. These are large-scale comparative effectiveness trials embedded in real clinical care settings — not standalone research facilities — comparing two or more interventions, exposures, or care strategies. Awards up to $30M over 4–6 years. The design requirement is pragmatism: the study must be feasible within routine care workflows, with eligibility criteria broad enough to reflect the actual patient population. Expect significant infrastructure investment in EHR integration and site coordination.
- Patient-Centered Outcomes Research (PCOR) Awards: A broader mechanism covering smaller comparative effectiveness studies, mixed-methods research, and observational studies with comparative elements. Awards typically $750K–$5M over 2–4 years. These are appropriate for early-career investigators or teams addressing well-defined comparative questions in a single disease area or patient population.
- Evidence Synthesis Awards: Systematic reviews, network meta-analyses, and rapid evidence reviews on comparative effectiveness questions from PCORI's prioritized research agenda. Awards up to $1.5M. PCORI publishes its evidence synthesis priorities annually — proposals that align with stated priorities score significantly higher.
- Pipeline to Proposal Awards: Capacity-building grants ($50K–$200K) designed for institutions or teams without prior PCORI funding that need support to develop a competitive full application. Priority given to organizations serving populations underrepresented in research. This is the right entry point if your team has the clinical expertise but hasn't done PCORI-style patient engagement or pragmatic trial design before.
The Patient Engagement Requirement: What Reviewers Actually Want to See
PCORI has been explicit about the minimum standard for patient engagement — and explicit that engagement that happens after the protocol is written doesn't count. The agency expects patient partners to be involved in: identifying and refining the research question, selecting outcomes that matter to patients, contributing to study design decisions (particularly eligibility criteria and outcome measures), interpreting results in context of patient experience, and co-creating dissemination materials.
- The Patient and Stakeholder Engagement Plan is a scored, required section of every PCORI application — not supplementary material. Reviewer scores on engagement quality directly affect funding decisions.
- PCORI provides a Patient Engagement Rubric and Checklist (available on pcori.org) that maps exactly to what reviewers evaluate. Use it to audit your engagement plan before submission.
- Patient partners must be compensated at rates appropriate to their expertise and time commitment. Underpaying patient partners is both ethically inconsistent with PCORI's stated values and a red flag for reviewers assessing whether your engagement is genuine.
- Document the engagement you've already done. Applications that describe what you plan to do with patients perform worse than those that show what you've already done with them during proposal development.
Application Process: Five Steps
- Step 1 — Review the current funding announcement on pcori.org/funding. Each announcement specifies priority populations, clinical areas, and study design requirements for that cycle. The Q2 2026 announcements updated the priority populations since Q4 2025 — don't assume the previous cycle's framing applies. The PCORI research agenda document is essential reading before you start writing.
- Step 2 — Attend the funding opportunity webinar. PCORI hosts webinars for each funding announcement. These are not optional background sessions — they include explicit guidance on what previous reviewer panels flagged as weaknesses, what the current priority emphases are, and what common errors look like in each section. Investigators who skip the webinar submit weaker proposals.
- Step 3 — Submit a Letter of Intent (LOI). Most PCORI mechanisms require a 2–3 page LOI before a full application is invited. PCORI provides written feedback on LOIs. The feedback is substantive and worth acting on — a LOI that receives "not recommended for full application" feedback can be revised and resubmitted if the issues are addressable. Don't skip the LOI feedback step.
- Step 4 — Build the full application around the five core sections: Research Plan (population, comparators, outcomes, design, analysis), Patient and Stakeholder Engagement Plan, Dissemination and Implementation Plan, Budget and Justification, and Team Qualifications. The Dissemination section is more important at PCORI than at NIH — reviewers assess whether you have a credible plan for getting your results into clinical practice, not just published in journals.
- Step 5 — Submit through PCORI's portal at pcori.org. PCORI does not use Grants.gov. Register early — the portal registration process for multi-investigator applications with institutional sign-off requires more lead time than most investigators expect.